The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The market size for chronic inflammatory demyelinating polyneuropathy (CIDP) has been expanding significantly in recent years. The market value is projected to rise from $2.10 billion in 2024 to $2.38 billion in 2025, with a compound annual growth rate (CAGR) of 8.4%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry?
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is predicted to develop significantly in the upcoming years, reaching a market size of $3.11 billion in 2029. This growth corresponds to a compound annu
Download Your Free Sample of the 2025 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The key drivers in the chronic inflammatory demyelinating polyneuropathy (cidp) market are:
• Rising global population, particularly aging demographics
• Greater focus on and increased awareness of rare diseases and autoimmune disorders
• Improved access to healthcare and enhanced healthcare infrastructure
• Advancements in treatment options and emergence of biosimilar therapies.
Global Market Segmentation: Identifying Major Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Segments
The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Pre-order the 2025 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The key trends in the chronic inflammatory demyelinating polyneuropathy (cidp) market are:
• An increasing prevalence of chronic inflammatory demyelinating polyneuropathy is an emerging trend.
• Advancements in treatment options for CIDP are becoming more prevalent.
• There is a growing trend of more extensive research and development activities related to CIDP.
• The emergence of biosimilar therapies and development of personalized medicine approaches are shaping the future of the CIDP market.
Who Are the Top Competitors & Leading Players in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Major players in the chronic inflammatory demyelinating polyneuropathy (cidp) market are:
• Pfizer Inc.
• Johnson & Johnson
• Sanofi SA
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Baxter International Inc.
• CSL Behring (CSL Limited)
• Grifols S.A.
• Sun Pharmaceutical Industries Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Octapharma AG
• Cipla Inc.
• Hikma Pharmaceuticals plc
• Halozyme Therapeutics
• Hualan Biological Engineering Inc
• argenx SE
• Hovione
• Nihon Pharmaceutical Co. Ltd.
• Bio Products Laboratory Ltd.
• AdvaCare Pharma
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024
